Outcome
    Moderate Evidence
    Effectiveness 4/5

    Vitamin B12 for Neuroprotection

    B12 keeps myelin intact and homocysteine low. Correcting deficiency prevents real, sometimes irreversible neurological damage; supplementing when replete has not been shown to protect the brain.

    Overview

    The neuroprotective case for vitamin B12 rests on homocysteine. B12, together with folate and B6, keeps homocysteine low, and elevated homocysteine is consistently associated with faster brain atrophy and cognitive decline in older adults. The most striking result comes from the VITACOG programme, where B-vitamin treatment slowed grey matter atrophy in regions vulnerable to Alzheimer disease, with the effect concentrated in participants whose baseline homocysteine was high.
    That conditionality is the whole story. Benefit appears where homocysteine is raised or B12 status is marginal; trials in replete populations have generally been null. B12 is therefore best understood as protecting against a specific, measurable deficit rather than as a general cognitive enhancer. Severe deficiency causes demyelination that can become irreversible, which is the strongest reason to identify and correct low status early.

    How It Works

    B12 is the cofactor for methionine synthase, which converts homocysteine back to methionine and generates S-adenosylmethionine, the universal methyl donor for DNA, neurotransmitter and phospholipid methylation. When B12 is scarce, homocysteine rises and methylation capacity falls. Elevated homocysteine is neurotoxic through excitotoxic and vascular routes, including endothelial dysfunction in small cerebral vessels.
    The second B12-dependent enzyme, methylmalonyl-CoA mutase, keeps odd-chain fatty acid metabolism running. Without it, methylmalonic acid accumulates and abnormal fatty acids are incorporated into myelin, producing unstable sheaths in peripheral nerves and spinal dorsal columns. This explains why B12 deficiency can present neurologically before any anaemia appears, and why prompt correction matters more than dose optimisation.

    Dosing & Protocol

    The VITACOG regimen combined 500 mcg B12 with 800 mcg folic acid and 20 mg B6 daily for two years. B12 alone at 500 to 1000 mcg per day is the common maintenance approach, and confirmed deficiency with neurological features is treated with intramuscular hydroxocobalamin first. Testing before treating is the important step: serum B12 plus, where borderline, methylmalonic acid or homocysteine.

    Measure homocysteine

    The atrophy benefit was seen in people with raised homocysteine. Testing tells you whether this intervention is likely to do anything at all.

    Evidence

    Three linked sources support this pairing: the 2013 PNAS report on preventing Alzheimer-related grey matter atrophy by B-vitamin treatment, a 2010 PLoS One B-vitamin supplementation trial examining homocysteine and cognitive function, and a 2006 Lancet Neurology review of vitamin B12 and neurological function. Together they support a homocysteine-mediated, status-dependent effect rather than a universal cognitive benefit.

    Studies linked to this pairing.

    Vitamin B12 and Neurological Function

    Score: 8/10
    2006

    Reynolds E

    Vitamin B12 deficiency causes a spectrum of neurological disturbances, and early recognition and repletion are essential to prevent irreversible damage.

    View source

    Homocysteine and Cognitive Function: B Vitamin Supplementation Trial

    Score: 8/10
    2010n=168

    Smith AD, Smith SM, de Jager CA +7 more

    The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins.

    View source

    Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment

    Score: 8/10
    2013
    rct
    n=156

    Douaud G, Refsum H, de Jager CA +4 more

    B-vitamin treatment reduced by as much as seven fold the cerebral atrophy in grey matter regions specifically vulnerable to the Alzheimer's disease process, in subjects with elevated homocysteine.

    View source

    Safety

    B12 is water soluble with no established upper intake level, and excess is excreted renally. High oral doses are routine and well tolerated. Injection-site discomfort and rare hypersensitivity to cobalamin are the main reported issues. The risk that matters is diagnostic rather than toxicological: supplementing before testing can normalise blood results and obscure the underlying cause, such as pernicious anaemia or malabsorption.

    Do not take folate alone

    High-dose folic acid can correct the anaemia of B12 deficiency while neurological damage continues. Check B12 before starting folate.

    Interactions & Conflicts

    Long-term metformin and acid-suppressing drugs both reduce B12 availability, the first by impairing ileal uptake and the second by limiting release of food-bound B12. Nitrous oxide irreversibly oxidises cobalamin and can precipitate acute neurological deterioration in someone already low, which is relevant to both anaesthesia and recreational use.
    Interacts withSeverityMechanismAction
    moderate
    		——
    moderate
    		——
    high
    		——
    high
    		——
    moderate
    		——

    References

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.